<DOC>
	<DOCNO>NCT01883180</DOCNO>
	<brief_summary>The purpose study compare incidence GVHD viral infection haploidentical hematopoietic stem cell transplant recipient receive different dose antithymocyte globulin ( ATG ) acute graft-versus-host disease ( aGVHD ) prophylaxis . Our first objective investigate optimal dose ATG aGVHD second object evaluate effect different dose ATG post-transplant viral infection .</brief_summary>
	<brief_title>ATG Haploidentical HSCT Acute Graft-versus-host Disease Prophylaxis</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) therapeutic option many hematological malignancy . Unfortunately , 75 % patient require allo-HSCT lack human leukocyte antigen ( HLA ) -matched donor . The alternative hematopoietic stem cell HLA-mismatched family donor . However , strategy , call haploidentical HSCT , may associate high risk early death severe GVHD . Opportunistic infection common complication allo-HSCT . Due absence effective preventive therapeutic drug virus , viral infection become one important cause death . The immunosuppression regimen include ATG show effective prevent severe GVHD haploidentical HSCT . But strategy delay immune reconstitution , therefore increase risk viral infection . The optimal dose different ATG preparation respect prevention GvHD fully understand today . The total dose 6 mg/kg 15 mg/kg effective prevention GVHD , dose 10 mg/kg may increase development viral infection . In trial , focus incidence aGVHD viral infection patient treat 7.5mg/kg 10mg/kg ATG . The incidence GVHD viral infection compare different dose arm .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>A patient age 1465 year Haploidentical hematopoietic stem cell transplant recipient Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>haploidentical hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Antithymocyte globulin</keyword>
	<keyword>viral infection</keyword>
</DOC>